. 2020 May;6(3):210-218.

doi: 10.1159/000504312. Epub 2019 Dec 11.

Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5

Christina Binder¹, Prithvi Mruthyunjaya^{2

3}, Amy C Schefler⁴, Michael I Seider^{5

6}, Richard Crilly¹, Arthur Hung¹, Sheridan Meltsner⁷, Yvonne Mowery⁷, David G Kirsch⁷, Bin S Teh⁸, Richard L S Jennelle⁹, Matthew T Studenski¹⁰, Wu Liu^{11

12}, Choonik Lee¹³, James A Hayman¹³, Brian Kastner¹⁴, Michael Hadsell¹⁵, Alison H Skalet^{1

16}

Affiliations

¹ Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon, USA.
² Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
³ Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, USA.
⁴ Retina Consultants of Houston, Houston, Texas, USA.
⁵ The Permanente Medical Group, San Francisco, California, USA.
⁶ Department of Ophthalmology, University of California, San Francisco, California, USA.
⁷ Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
⁸ Department of Radiation Oncology, Houston Methodist Cancer Center, Houston, Texas, USA.
⁹ Department of Radiation Oncology, University of Southern California Medical Center, Los Angeles, California, USA.
¹⁰ Department of Radiation Oncology/Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
¹¹ Department of Radiation Oncology, Stanford University, Palo Alto, California, USA.
¹² Department of Therapeutic Radiology, Yale University and Yale-New haven Hospital, New Haven, Connecticut, USA.
¹³ Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
¹⁴ Radiation Oncology Centers, PC, Spectrum Health, Grand Rapids, Michigan, USA.
¹⁵ Department of Radiation Oncology, Porter Adventist, Centura Health, Denver, Colorado, USA.
¹⁶ Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.

PMID: 32509767
PMCID: PMC7250354
DOI: 10.1159/000504312

Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5

Christina Binder et al. Ocul Oncol Pathol. 2020 May.

. 2020 May;6(3):210-218.

doi: 10.1159/000504312. Epub 2019 Dec 11.

Authors

Affiliations

¹ Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon, USA.
² Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, USA.
³ Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, USA.
⁴ Retina Consultants of Houston, Houston, Texas, USA.
⁵ The Permanente Medical Group, San Francisco, California, USA.
⁶ Department of Ophthalmology, University of California, San Francisco, California, USA.
⁷ Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
⁸ Department of Radiation Oncology, Houston Methodist Cancer Center, Houston, Texas, USA.
⁹ Department of Radiation Oncology, University of Southern California Medical Center, Los Angeles, California, USA.
¹⁰ Department of Radiation Oncology/Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
¹¹ Department of Radiation Oncology, Stanford University, Palo Alto, California, USA.
¹² Department of Therapeutic Radiology, Yale University and Yale-New haven Hospital, New Haven, Connecticut, USA.
¹³ Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
¹⁴ Radiation Oncology Centers, PC, Spectrum Health, Grand Rapids, Michigan, USA.
¹⁵ Department of Radiation Oncology, Porter Adventist, Centura Health, Denver, Colorado, USA.
¹⁶ Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.

PMID: 32509767
PMCID: PMC7250354
DOI: 10.1159/000504312

Abstract

Background: Treatment planning for I-125 plaque therapy for uveal melanoma has advanced significantly since the Collaborative Ocular Melanoma Study trial, with more widely available image-guided planning and improved dosimetry.

Objective: We evaluated real-world practice patterns for I-125 plaque brachytherapy in the United States by studying practice patterns at centers that comprise the Ocular Oncology Study Consortium (OOSC).

Methods: The OOSC database and responses to a treatment practice survey were evaluated. The database contains treatment information from 9 institutions. Patients included in the database were treated between 2010 and 2014. The survey was conducted in 2018 and current treatment planning methods and prescriptions were queried.

Results: Examination of the OOSC database revealed that average doses to critical structures were highly consistent, with the exception of one institution. Survey responses indicated that most centers followed published guidelines regarding dose and prescription point. Dose rate ranged from 51 to 118 cGy/h. As of 2018, most institutions use pre-loaded plaques and fundus photographs and/or computed tomography or magnetic resonance imaging in planning.

Conclusions: While there were differences in dosimetric practices, overall agreement in plaque brachytherapy practices was high among OOSC institutions. Clinical margins and planning systems were similar among institutions, while prescription dose, dose rates, and dosimetry varied.

Keywords: Brachytherapy; Treatment practices; Uveal melanoma.

PubMed Disclaimer

Conflict of interest statement

P.M.: consultant − Castle Biosciences, Optos Inc.; personal fees − Santen, Spark Therapeutics. J. William Harbour: consultant and royalties − Castle Biosciences. Miguel Materin and A.C.S.: consultant − Castle Biosciences. Thomas Aaberg Jr.: consultant − Castle Biosciences, Alcon, Baush, and Lomb, True Vision, Regeneron. Peter Hovland: advisory panel − Castle Biosciences. D.G.K.: scientific advisory board, own equity, and royalties − Lumicell Inc., co-founder and own equity − XRAD therapeutics. Research support: Merck, Eli Lilly, and Bristol-Myers Squibb. Jesse Berry: consultant − Immunocore. A.H.S.: consultant − Castle Biosciences, Immunocore. The other authors have no conflicts of interest to disclose.

Figures

**Fig. 1**
Choice of plaque size and clinical margin. a Plaque size increases with largest basal diameter. Mean and SD are shown. b There is no difference in clinical margin per plaque size. Mean and SD are shown. c 2–3 mm is the most common clinical margin, and ≤2 and 3–4 mm are also prevalent. d Peripapillary lesions were treated with the largest clinical margins.

See this image and copyright information in PMC

Cited by

Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy.
Bolling JP, Dagan R, Rutenberg M, Mamalui-Hunter M, Buskirk SJ, Heckman MG, Hochwald AP, Slopsema R. Bolling JP, et al. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec 22;6(1):27-36. doi: 10.1016/j.mayocpiqo.2021.10.002. eCollection 2022 Feb. Mayo Clin Proc Innov Qual Outcomes. 2021. PMID: 35005435 Free PMC article.
Innovations in brachytherapy.
Lim J, Teo AWJ, Siow TR, Chan KP, Tan GSW. Lim J, et al. Taiwan J Ophthalmol. 2025 Feb 25;15(1):62-72. doi: 10.4103/tjo.TJO-D-24-00108. eCollection 2025 Jan-Mar. Taiwan J Ophthalmol. 2025. PMID: 40213297 Free PMC article. Review.
Contemporary trends in management of uveal melanoma.
Chevli N, Zuhour RJ, Messer JA, Haque W, Schefler AC, Bernicker EH, Chevez-Barrios P, Farach AM, Butler EB, Teh BS. Chevli N, et al. J Contemp Brachytherapy. 2022 Apr;14(2):123-129. doi: 10.5114/jcb.2022.115210. Epub 2022 Apr 2. J Contemp Brachytherapy. 2022. PMID: 35494177 Free PMC article.
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ, Paduszyńska N, Solnik M, Toro MD, Bilmin K, Bylina E, Rutkowski P, Yousef YA, Bucolo C, Zweifel SA, Reibaldi M, Fiedorowicz M, Czarnecka AM. Synoradzki KJ, et al. Curr Oncol. 2024 Feb 1;31(2):778-800. doi: 10.3390/curroncol31020058. Curr Oncol. 2024. PMID: 38392052 Free PMC article. Review.
The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.
Holik HA, Ibrahim FM, Elaine AA, Putra BD, Achmad A, Kartamihardja AHS. Holik HA, et al. Molecules. 2022 May 10;27(10):3062. doi: 10.3390/molecules27103062. Molecules. 2022. PMID: 35630536 Free PMC article. Review.

References

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011 Sep;118((9)):1881–5. - PubMed
1. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. Collaborative Ocular Melanoma Study Group The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001 Jul;119((7)):969–82. - PubMed
1. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. Control Clin Trials. 1993 Oct;14((5)):362–91. - PubMed
1. Simpson ER, Gallie B, Laperrierre N, Beiki-Ardakani A, Kivelä T, Raivio V, et al. American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com. ABS − OOTF Committee The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014 Jan-Feb;13((1)):1–14. - PubMed
1. Chiu-Tsao ST, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys. 2012 Oct;39((10)):6161–84. - PubMed

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5

Affiliations

Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Research Materials

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Research Materials